Primary Sclerosing Cholangitis Market Size, Share, By Drug (BT1023, GS-9674, NGM282, OCA, LUM001, and Others), By Type (Classic PSC, Small-duct PSC and PSC Associated with Autoimmune Hepatitis), Treatment Type (Ursodeoxycholic Acid, Obeticholic Acid, Methotrexate, Corticosteroids and Others), Symptom Control (Antihistamines, Cholestyramine, Antibacterials, Opioid Antagonists, Colestipol and Others), End User (Hospital Pharmacies, and Retail Pharmacies), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa) - Trends, Analysis and Forecast till 2034

Primary Sclerosing Cholangitis Market Size was valued at USD 337 Million in 2024 and is expected to reach USD 661 Million by 2034, growing at a CAGR of 7.7%

Primary Sclerosing Cholangitis (PSC) is chronic cholestatic liver disease, which primarily affects young and middle aged man. PSC slowly damages bile duct by inflammation and scarring or fibrosis which eventually leads to blockage of bile ducts. PSC is autoimmune disease which can leads to cirrhosis which finally leads to liver failure. Particularly, men between the ages of 30 and 50 years, and being diagnosed with any inflammatory bowel disease (IBD) are likely to get primary sclerosing cholangitis (PSC).

Increasing number of research and development activities combined with ongoing clinical trial studies on primary sclerosing cholangitis to understand its mechanisms and risk factors by various healthcare regulatory bodies and government agencies are some among the major factors expected to drive growth of the market. For instance, in September 2018, the U.S. Food and Drug Administration (FDA) awarded 12 new clinical trial research grants of more than US$ 18 million for next four year to enhance the development of medical products for patients with rare diseases. These research grants are awarded to principal investigators from academic institutions and industry across the U.S.  Growing incidence of liver failure and bile cancer associated with PSC and future launch of PSC drugs which currently in clinical phase III are expected to offer lucrative growth opportunities in the near future.

Key Drivers of Target Market:

Expanding PSC Diagnoses

• Higher frequency of PSC diagnoses due to better diagnostic tools and increased awareness that leads to earlier and more frequent diagnosis. Why? Well, that might be because of the advancement in non-invasive techniques of imaging and a rising connect between PSC and Ulcerative Colitis, which is itself getting increasingly common. The earlier the diagnosis, the earlier intervention and management of disease.
• Pharmaceutical companies are engaged in developing novel therapies targeting basic mechanisms of PSC by modulation of the immune system, specific bile acid imbalances associated with PSC, or other targets to achieve disease modification beyond just symptom management. This includes drugs that modulate the immune system or act upon certain bile acid imbalances associated with PSC. On the horizon is a robust pipeline of drugs at various phases of study that now brings hope of more effective therapy for patients afflicted by PSC.

Technological advances

• The diagnosis and treatment of PSC are changing with new technologies. Magnetic resonance cholangiopancreatography is a fully non-invasive investigation of very high accuracy in the visualization of the bile ducts and, therefore, diagnosis of PSC. On its part, advances in endoscopic techniques put ERCP in a different position to manage the complications ensuing from the involvement of bile ducts—the hallmark feature of PSC—in a minimally invasive manner. These technological advancements bringissance controversies diagnostic accuracy and enhance treatment effectiveness.
• Liver transplantation remains the definite treatment option for patients with advanced PSC experiencing liver failure.  Improving surgical techniques and the advent of increasingly effective immunosuppressive agents have contributed to the rise in the number of successful transplant procedures.  The increasing availability of liver transplantation as a treatment option is another driver of the market's growth.

Restrains:

Limited Treatment Options

• While the pipeline looks very promising in the future, the current therapeutics market for PSC is yet limited. These medications do not cure the diseases but rather look at amelioration and one that slows down its progress. The efficacy of these medications can also differ significantly from case to case. Lack of any definitive cure and very limited treatment options have resulted in extraordinary unmet medical needs in the market for the disease.
• The high cost is the single biggest barrier to the treatment of PSC.  Indeed, the financial outlay for medications and procedures such as ERCP, and future therapies that might become available, is large for both patients and healthcare systems.  Therefore, cost-effective treatment solutions and strategies that would provide more patients with access to these therapies will be important for the long-term sustainability of the market.

Opportunities:

Novel Therapies Development

• As noted above, the strong pipeline of drugs targeting PSC causes presents a remarkable opportunity. The market is ready for those medications that will effectively modulate the immune system or address bile acid imbalances to bring about disease modification and improvement in patient outcomes, hence making a significant expansion in treatment options and better quality of life for patients.

Precision Medicine Approaches

• A better understanding of the genetic and molecular underpinnings of PSC paves the way for personalized treatment strategies. It means that tailored treatment for diseases in every single patient, wholly based on his/her case profile, can result in concentrating actions to a much more focused treatment plan. This impacts treatment efficacy and reduces side effects to a minimum.

Diagnostic and monitoring tools that are non-invasive

• The further development of noninvasive diagnostic instruments, such as sophisticated imaging techniques and blood tests, is very helpful in early detection and monitoring of diseases. Consequently, this would prove to be quite advantageous to the patients themselves, allowing for earlier intervention, and would also provide opportunities for companion diagnostics—selection of patients most likely to benefit from particular therapies.

Improved delivery systems

• Novel drug delivery systems, such as sustained-release formulations or selective treatment, can improve medication compliance and overall treatment effectiveness. The development of these delivery systems presents the significant opportunity to complement the currently deficits of PSC treatment in order to improve patient outcomes.

The market is segmented based on Drug, By Type, Treatment Type, Symptom control, End-User, and Region.

Drug Insights:

• BT1023 (Build-a-Molecule): BT1023 is a first-in-class, investigational oral medicine in development by Build-a-Molecule to treat PSC. It works by blocking a specific protein involved in the inflammatory response of the immune system and so could have a diseased-modifying effect. BT1023 is currently under phase 2a clinical trials for its safety evaluation in efficacy in patients with PSC.
• GS-9674: GS-9674 is an investigational, selective FXR inhibitor—a bile acid receptor—in development by Gilead Sciences. The goal of GS-9674 in targeting FXR is to modulate bile acid signaling and address the attendant underlying mechanisms of PSC. GS-9674 is in Phase 2b clinical trials intended for assessing its safety and effectiveness in patients with PSC.
• Another investigative drug in development is NGM282 by Nimbus Therapeutics. It is directed against an immunological signaling pathway thought to be involved in PSC pathogenesis. The Phase 2 studies of NGM282 are underway to determine its safety and efficacy in PSC patients.
• OCA (Odyssey Therapeutics): OCA refers to an Odyssey Cholangiography contrast agent, specifically designed for enhancing the ability to visualize bile ducts during an MRCP examination. As visualization of bile ducts increases, it helps in the diagnosis of PSC and other cholangiopathies. OCA is available commercially in the United States and Europe and is poised for growing adoption as PSC diagnoses rise.
• LumiraDx, LUM001—LumiraDx is developing a blood test that has the potential to non-invasively diagnose PSC. This would be a very promising development against existing methods of diagnosis that include ERCP, potentially providing an invasive and complication-entailing approach. Although LUM001 is still under study, it offers great hope for further improvement in PSC diagnosis and patient care.
• Other Drugs: Several other drugs are in use today for symptomatic management and limitation of progression in PSC patients, like ursodeoxycholic acid and corticosteroids. However, none of the above-mentioned medications affect the basic processes of the disease. The continuous development of new therapies with potential to modify the course of the disease will probably dramatically change the approach to treating PSC within the next years.

Type Insights:

• Classic PSC: This is the most common variant of PSC and comprises 60-70% of diagnosed cases. A progressive inflammatory process narrows large bile ducts situated outside the liver. Narrowed ducts are likely to block the free flow of the bile and bring about further complications involving liver damage, malnutrition, and tiredness.
• Small-duct PSC: The type of smaller bile ducts is located within the liver itself. Diagnosis is more difficult and typically has a milder symptom profile compared to classic typical PSC, as conventional imaging modalities have low sensitivity. However, small-duct PSC can progress to involve larger bile ducts with similar complications to classic PSC over time.
• AIH associated with PSC: Some 10–15% of the patients suffering from PSC are concurrently involved with AIH, which is another autoimmune disease attacking the liver. Coexistence may have particular challenges for treatment methods since both need to be managed. The guidelines for this understanding are important in optimizing treatment strategies for this patient population.

Treatment type Insights

• Ursodeoxycholic Acid (UDCA): First line medication in most patients with PSC. The mode of action is promoting bile flow and possibly having a protective effect on hepatocytes. It is generally well-tolerated with few side effects. This does not alter the underlying cause of the process of PSC and may not be effective in all cases.
• Obeticholic acid: The activation of FXR may regulate either the metabolism of bile acids or induce anti-inflammatory effects. Thus, it is promising in clinical trials for PSC. Still, it has to be proved in well-designed randomized controlled trials regarding its exact role. Relatively new with ongoing research to determine the long-term efficacy and safety profile in patients with PSC.
• Methotrexate Drugs: represent drugs used to dampen excessive immune responses in PSC. May be helpful in some patients with autoimmune features or inflammatory complications. Can have significant side effects, and their effectiveness in PSC is not universally established. Close physician monitoring will be required.
• Corticosteroids: Primarily used to reduce the severe itching, which is one of the prevalent symptoms of PSC, for a short term. It quite effectively controls itching but may lead to serious side effects if taken for a long time. Thus, it cannot provide any long-term remedies because of potential side effects like weight gain, bone weakening, and chances of infection.
• Other Treatment Options: Some of them include: Endoscopic Retrograde Cholangiopancreatography, Liver Transplant, Dietary and Lifestyle Changes, etc.

Symptom Control Insights:

• Antihistamines: Relieve itching, a common and often disabling symptom of PSC. Diphenhydramine Benadryl, Loratadine Claritin Block histamine, a chemical released by the body that stimulates itching sensations. Can cause drowsiness; may not be effective for all types of itching associated with PSC.
• Cholestyramin (Questran): The medication lowers itching and is also of help in managing diarrhea, another common feature in some PSC patients. This agent binds bile acids within the gut and thereby prevents them from reabsorption into circulation, which otherwise might cause itchiness. It can cause constipation, bloating, and interfere with the absorption of vitamins and some medications. Require close monitoring and dosage adjustments.
• Antibacterials: Used to treat bacterial cholangitis, which is an iatrogenic complication occurring as a result of infection with PSC in the bile ducts. Gr. examples include amoxicillin and ciprofloxacin. How they work: Kill all bacteria that cause an infection. Antibiotics must be taken only upon prescription by a doctor for the prescribed period of time, in order to avoid resistance to antibiotics.
• Opioid Antagonals: Treat intractable pruritus unresponsive to other measures; one such medication is Naltrexone - Inhibit effects of opioids on the brain; an unintended consequence of these medications can be an exaggerated itch in some patients. Known undesirable side effects include nausea, vomiting, and muscle pains are not first line therapy due to its potential side effects.
• Colestipol (Colestid): Like Cholestyramine, Colestipol is also linked to bile acids and is useful in managing itching and diarrhea. It can be given as an alternative to Cholestyramine if a patient develops some side effects.
• Other Drugs: Antidepressants and anxiolytics are sometimes prescribed to help reduce stress and improve the quality of sleep. This indirectly helps in the control of symptoms.

End-User Insight:

• Hospital Pharmacies: These are pharmacies that directly dispense medications to patients who are admitted to a Health Care Facility for treatment. In relation to PSC, hospital medications could be issued to the patient during an admission for the management of complications or performance of procedures associated with the illness.
• Retail Pharmacies: These are community pharmacies outside the setup of the hospital that dispense medications to outpatients with prescriptions from healthcare professionals. Most patients with PSC will source their long-term medications for the management of the condition from retail pharmacies. Pharmacists in these settings have a very important role in counseling on medications, side effects, and how to use them. They will thus be in a good position to answer queries and provide support in the management of symptoms associated with PSC.

Regional Insights

• North America: The North American VPP market is propelled by modern energy infrastructure, favorable policies, and a significant emphasis on grid stability. The United States and Canada are the leaders in adoption, focusing on demand response programs, EV charging network integration, and the use of AI in VPP administration.
• Asia Pacific: The Asia Pacific area is poised for solid expansion in the VPP market, owing to rising energy consumption, rapid urbanization, and increased renewable energy use. Government measures to modernize electrical systems and increase dependability are critical.
• Europe: Europe is on track to become the world’s largest VPP market, powered by ambitious renewable energy objectives and severe decarbonization aspirations. The region's strong, smart grid infrastructure and supportive legislative framework, such as the EU's Clean Energy Package, allow for rapid VPP implementation.
• Latin America: The VPP market in Latin America is predicted to rise gradually, driven by increased renewable energy usage, particularly hydropower and solar, as well as initiatives to modernize aging grid infrastructure. The region aims to improve grid stability, reduce power outages, and increase energy efficiency through demand-side management.
• Middle East and Africa: This region is seeing increased interest in VPPs, particularly in countries with high renewable energy objectives and needing greater grid stability. VPPs are viewed as a solution for managing peak demand in fast-developing urban regions while supporting rural electrification efforts.

Primary Sclerosing Cholangitis Market Report Scope:

Attribute	Details
Market Size 2024	US$ 337 Million
Projected Market Size 2034	US$ 661 Million
CAGR Growth Rate	7.7%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Million & CAGR from 2024 to 2034
Market Segmentation	By Drug- BT1023, GS-9674, NGM282, OCA, LUM001, and Others By Type- Classic PSC, Small-duct PSC and PSC Associated with Autoimmune Hepatitis By Treatment Type- Ursodeoxycholic Acid, Obeticholic Acid, Methotrexate, Corticosteroids and Others By Symptom Control- Antihistamines, Cholestyramine, Antibacterials, Opioid Antagonists, Colestipol and Others By End User- Hospital Pharmacies, and Retail Pharmacies
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on on Drug, By Type, Treatment Type, Symptom control, End-User, and Region.

By Technology:

• BT1023
• GS-9674
• NGM282
• OCA
• LUM001
• Others

By Type:

• Classic PSC
• Small-duct PSC
• PSC Associated with Autoimmune Hepatitis

By Treatment type:

• Ursodeoxycholic Acid
• Obeticholic Acid
• Methotrexate
• Corticosteroids
• Others

By Symptom Control:

• Antihistamines
• Cholestyramine
• Antibacterials
• Opioid Antagonists
• Colestipol
• Others

By End-User:

• Hospital Pharmacies
• Retail Pharmacies

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Primary Sclerosing Cholangitis Market include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen High Tide Biopharmaceutical Ltd.

• In June 2024, Pliant Therapeutics, a clinical-stage biopharmaceutical company developing treatments for cholangiopathies, reported positive results from its Phase 2a clinical trial using investigational compound PLN-74809, now commercially known as bexotegrast, in treating PSC. In this study, PLN-74809 was well-tolerated and safe, and activity signals of the drug emerged from improvements in liver function markers for people with PSC.
• In April 2024, The National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health increased support for research on the cholangiopathies, including PSC. Added funding will further research the causes of PSC and develop novel therapeutic strategies.

• Acorda Therapeutics, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Gilead Sciences, Inc.
• NGM Biopharmaceuticals, Inc.
• Intercept Pharmaceuticals, Inc.
• Dr. Falk Pharma GmbH
• Allergan Plc.
• Shire Plc.
• Durect Corporation
• Conatus Pharmaceuticals, Inc.
• Sirnaomics, Inc.
• Shenzhen HighTide Biopharmaceutical Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug
  • Market Snippet, By Type
  • Market Snippet, By Treatment type
  • Market Snippet, By Symptom control
  • Market Snippet, By End-User
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Drug, Forecast Period up to 10 Years, (US$ Mn)

• Overview
  • Market Value and Forecast (US$ Mn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• BT1023
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• GS-9674
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• NGM282
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

• OCA
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• LUM001
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Others
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Type, Forecast Period up to 10 Years, (US$ Mn)

• Overview
  • Market Value and Forecast (US$ Mn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Classic PSC
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Small-duct PSC
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• PSC Associated with Autoimmune Hepatitis
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Treatment type, Forecast Period up to 10 Years, (US$ Mn)

• Overview
  • Market Value and Forecast (US$ Mn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Ursodeoxycholic Acid
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Obeticholic Acid
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Methotrexate
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

• Corticosteroids
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Others
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Symptom Control, Forecast Period up to 10 Years, (US$ Mn)

• Overview
  • Market Value and Forecast (US$ Mn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Antihistamines
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Cholestyramine
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Antibacterials
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Opioid Antagonists
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Colestipol
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, End-User, Forecast Period up to 10 Years, (US$ Mn)

• Overview
  • Market Value and Forecast (US$ Mn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Retail Pharmacies
  • Overview
  • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (US$ Mn)

• Overview
  • Market Value and Forecast (US$ Mn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Mn), By Drug, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Symptom Control, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (US$ Mn), By Drug, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Symptom Control, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (US$ Mn), By Drug, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Symptom Control, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (US$ Mn), By Drug, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Symptom Control, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (US$ Mn), By Drug, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Treatment Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Symptom Control, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Mn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Acorda Therapeutics, Inc.
• Gilead Sciences, Inc.
• NGM Biopharmaceuticals, Inc.
• Intercept Pharmaceuticals, Inc.
• Dr. Falk Pharma GmbH
• Allergan Plc.
• Shire Plc.
• Durect Corporation
• Conatus Pharmaceuticals, Inc.
• Sirnaomics, Inc.
• Shenzhen HighTide Biopharmaceutical Ltd.

The Last Word

• Future Impact
• About Us
• Contact